在成年人中，牛津/阿斯利康疫苗在第 2 剂接种后 14 天以上对 COVID-19 的有效率为 70%。

In adults, the Oxford/AstraZeneca vaccine had 70% efficacy against COVID-19 >14 d after the 2nd dose.

机构信息

McMaster University, Hamilton, Ontario, Canada (Z.C.).

出版信息

Ann Intern Med. 2021 Mar;174(3):JC29. doi: 10.7326/ACPJ202103160-029. Epub 2021 Mar 2.

DOI:10.7326/ACPJ202103160-029

PMID:33646835

Abstract

Voysey M, Clemens SA, Madhi SA, et al. Lancet. 2021;397:99-111. 33306989.

摘要

Voysey M, Clemens SA, Madhi SA, et al. Lancet. 2021;397:99-111. 33306989.

相似文献

In adults, the Oxford/AstraZeneca vaccine had 70% efficacy against COVID-19 >14 d after the 2nd dose.在成年人中，牛津/阿斯利康疫苗在第 2 剂接种后 14 天以上对 COVID-19 的有效率为 70%。

Ann Intern Med. 2021 Mar;174(3):JC29. doi: 10.7326/ACPJ202103160-029. Epub 2021 Mar 2.

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.ChAdOx1 nCoV-19 疫苗（阿斯利康）对 SARS-CoV-2 的安全性和有效性：巴西、南非和英国四项随机对照试验的中期分析。

Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. Epub 2020 Dec 8.

In South Africa, a 2-dose Oxford/AZ vaccine did not prevent mild to moderate COVID-19 (cases mainly B.1.351 variant).在南非，两剂牛津/阿斯利康疫苗未能预防轻症至中症 COVID-19（病例主要为 B.1.351 变异株）。

Ann Intern Med. 2021 May;174(5):JC50. doi: 10.7326/ACPJ202105180-050. Epub 2021 May 4.

Oxford-AstraZeneca COVID-19 vaccine efficacy.牛津大学-阿斯利康新冠疫苗的效力

Lancet. 2021 Jan 9;397(10269):72-74. doi: 10.1016/S0140-6736(20)32623-4. Epub 2020 Dec 8.

Sustained COVID-19 vaccine willingness after safety concerns over the Oxford-AstraZeneca vaccine.对牛津-阿斯利康疫苗的安全性担忧后，对 COVID-19 疫苗的持续意愿。

Dan Med J. 2021 Mar 31;68(5):A03210292.

Oxford COVID-vaccine paper highlights lingering unknowns about results.牛津大学关于新冠疫苗的论文凸显了研究结果中仍存在的未知因素。

Nature. 2020 Dec;588(7838):378-379. doi: 10.1038/d41586-020-03504-w.

In high-risk adults, the Moderna vaccine had 94% efficacy against COVID-19 ≥14 d after the 2nd dose.在高风险成年人中，第二剂接种后≥14 天， Moderna 疫苗对 COVID-19 的有效性为 94%。

Ann Intern Med. 2021 Mar;174(3):JC28. doi: 10.7326/ACPJ202103160-028. Epub 2021 Mar 2.

Acute Transverse Myelitis (ATM):Clinical Review of 43 Patients With COVID-19-Associated ATM and 3 Post-Vaccination ATM Serious Adverse Events With the ChAdOx1 nCoV-19 Vaccine (AZD1222).急性横贯性脊髓炎（ATM）：43例新冠病毒相关急性横贯性脊髓炎患者及3例接种ChAdOx1 nCoV-19疫苗（AZD1222）后发生的急性横贯性脊髓炎严重不良事件的临床回顾

Front Immunol. 2021 Apr 26;12:653786. doi: 10.3389/fimmu.2021.653786. eCollection 2021.

BioNTech/Pfizer vaccine after Oxford/AZ vaccine increased immune response vs. no second vaccine.辉瑞/生物科技疫苗接种后，与不接种第二剂疫苗相比，免疫反应增强。

Ann Intern Med. 2021 Nov;174(11):JC123. doi: 10.7326/ACPJ202111160-123. Epub 2021 Nov 2.

The BNT162b2 (BioNTech/Pfizer) vaccine had 95% efficacy against COVID-19 ≥7 days after the 2nd dose.BNT162b2（辉瑞/生物科技）疫苗在第 2 剂接种后 ≥7 天对 COVID-19 的有效率为 95%。

Ann Intern Med. 2021 Feb;174(2):JC15. doi: 10.7326/ACPJ202102160-015. Epub 2021 Feb 2.

引用本文的文献

SARS-CoV-2-Specific Antibodies, B Cell and T Cell Immune Responses after ChAdOx1 nCoV-19 Vaccination in Solid Organ Transplant Recipients.实体器官移植受者接种ChAdOx1 nCoV-19疫苗后针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的抗体、B细胞和T细胞免疫反应

Vaccines (Basel). 2024 May 15;12(5):541. doi: 10.3390/vaccines12050541.

Long COVID in the context of social determinants of health.长新冠在健康社会决定因素方面的问题。

Front Public Health. 2023 Mar 28;11:1098443. doi: 10.3389/fpubh.2023.1098443. eCollection 2023.

Challenges and Recent Advancements in COVID-19 Vaccines.新冠疫苗面临的挑战与近期进展

Microorganisms. 2023 Mar 18;11(3):787. doi: 10.3390/microorganisms11030787.

Regulating the microenvironment with nanomaterials: Potential strategies to ameliorate COVID-19.用纳米材料调节微环境：改善新型冠状病毒肺炎的潜在策略。

Acta Pharm Sin B. 2023 Feb 21;13(9):3638-58. doi: 10.1016/j.apsb.2023.02.010.

Reduction in COVID-19 Vaccine Effectiveness against SARS-CoV-2 Variants in Seoul according to Age, Sex, and Symptoms: A Test-Negative Case-Control Study.根据年龄、性别和症状，首尔地区 COVID-19 疫苗对 SARS-CoV-2 变异体有效性降低：一项病例对照研究。

Int J Environ Res Public Health. 2022 Dec 16;19(24):16958. doi: 10.3390/ijerph192416958.

COVID-19 cross-sectional study in Maricá, Brazil: The impact of vaccination coverage on viral incidence.巴西马里卡的 COVID-19 横断面研究：疫苗接种覆盖率对病毒发病率的影响。

PLoS One. 2022 Sep 19;17(9):e0269011. doi: 10.1371/journal.pone.0269011. eCollection 2022.

Local myofascitis of the deltoid muscle after administration of the AstraZeneca (AZD1222) COVID-19 vaccine: two cases, infectious and inflammatory.接种阿斯利康（AZD1222）新冠疫苗后三角肌局部肌筋膜炎：两例感染性和炎症性病例

JSES Rev Rep Tech. 2022 Aug;2(3):376-379. doi: 10.1016/j.xrrt.2022.04.005. Epub 2022 May 10.

New relapse of multiple sclerosis and neuromyelitis optica as a potential adverse event of AstraZeneca AZD1222 vaccination for COVID-19.新型多发性硬化症和视神经脊髓炎复发，可能是阿斯利康 AZD1222 新冠疫苗的不良反应。

Mult Scler Relat Disord. 2022 Jan;57:103321. doi: 10.1016/j.msard.2021.103321. Epub 2021 Oct 13.

Incidence and severity of COVID-19 infection post-vaccination: a survey among Indian doctors.接种疫苗后 COVID-19 感染的发生率和严重程度：一项针对印度医生的调查。

Infection. 2022 Aug;50(4):889-895. doi: 10.1007/s15010-022-01758-2. Epub 2022 Feb 7.

Vaccination Opportunities in Multiple Sclerosis Patients Treated with Cladribine Tablets. cladribine 片剂治疗多发性硬化症患者的接种机会。

Curr Neuropharmacol. 2022;20(10):1811-1815. doi: 10.2174/1570159X20666211217160451.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

在成年人中，牛津/阿斯利康疫苗在第 2 剂接种后 14 天以上对 COVID-19 的有效率为 70%。

In adults, the Oxford/AstraZeneca vaccine had 70% efficacy against COVID-19 >14 d after the 2nd dose.

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献